Stryker announced a definitive agreement to acquire Amplitude Vascular Systems, a Boston‑based developer of next‑generation intravascular lithotripsy (IVL) technology, on April 13, 2026. The deal adds Amplitude’s CO₂‑generated pressure‑wave IVL platform to Stryker’s peripheral vascular portfolio, enhancing revascularization capabilities for calcified peripheral arterial disease.
The acquisition follows Stryker’s February 2025 purchase of Inari Medical for $4.9 billion, which bolstered its peripheral vascular offerings. By adding Amplitude’s investigational Pulse IVL system, Stryker aims to capture the growing market for advanced calcium‑modification therapies and position itself to compete with Shockwave Medical and other IVL players.
Amplitude, founded in 2017 and backed by $66.3 million in funding, has not yet received regulatory clearance for its Pulse IVL system. The technology uses CO₂‑generated pressure waves to fracture calcium deposits, offering a potential next‑generation alternative to existing IVL solutions. The acquisition is expected to accelerate regulatory approval and commercialization timelines.
Stryker’s recent financial performance underscores the strategic fit. In Q1 2025, the company reported net sales of $5.9 billion, up 11.9%, and adjusted EPS of $2.84, beating estimates. For 2026, Stryker projects organic net sales growth of 8.0%–9.5% and adjusted EPS of $14.90–$15.10. The acquisition is expected to contribute to these growth targets by expanding the product mix and opening new revenue streams in peripheral interventions.
The deal terms remain undisclosed, but the transaction is part of Stryker’s broader M&A strategy to build a comprehensive vascular platform. The company has integrated several acquisitions in recent years, including Vertos Medical, NICO, and Inari, and plans to continue expanding its portfolio. The acquisition also comes amid a cybersecurity incident in March 2026 that disrupted operations, but Stryker has stated confidence in meeting its 2026 guidance.
Management emphasized the strategic importance of the acquisition. CEO Kevin Lobo said the deal “represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs.” The addition of Amplitude’s technology is expected to enhance treatment options for physicians and improve care for patients with calcified peripheral arterial disease.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.